Log in to search using one of your social media accounts:

 

Secondary intracranial hypertension (pseudotumor cerebri) presenting as post-traumatic headache in mild traumatic brain injury: a case series - Sabo T, Supnet C, Purkayastha S.
BACKGROUND: Cerebral edema peaks 36-72  h after moderate traumatic brain injury but thought to be uncommon after mild traumatic brain injury. Post-traumatic headache can develop 48-72 h post-injury, perhaps reflecting the developing cerebral edema. Pseudo... (Source: SafetyLit)
Source: SafetyLit - December 14, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

40 years after first Ebola outbreak, survivors show signs they can stave off new infection
Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks, according to a new study led by researchers at the UCLA Fielding School of Public Health.UCLA researchers located the 14 Ebola survivors of the 1976 outbreak who, in January 2016, were still living in the same small, remote villages in the forests of the Équateur Province of northwestern Democratic Republic of the Congo. The researchers obtained blood samples and health history reports from them. The data revealed evidence ...
Source: UCLA Newsroom: Health Sciences - December 14, 2017 Category: Universities & Medical Training Source Type: news

Another Legacy of Terror Attacks: Migraines
Title: Another Legacy of Terror Attacks: MigrainesCategory: Health NewsCreated: 12/13/2017 12:00:00 AMLast Editorial Review: 12/14/2017 12:00:00 AM (Source: MedicineNet Migraine General)
Source: MedicineNet Migraine General - December 14, 2017 Category: Neurology Source Type: news

Prescribing Oxygen for Cluster Headache: A Guide Prescribing Oxygen for Cluster Headache: A Guide
While oxygen is the standard of care for acute treatment of cluster headache, Medicaid and Medicare don't cover it; other insurers may. Learn how to properly prescribe it in this brief article.Headache (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Another Legacy of Terror Attacks: Migraines
Norwegian researchers examined the aftermath of a 2011 terrorist attack on a summer camp in Norway that left 69 people dead and 33 severely wounded. Most of the dead were teenagers. (Source: WebMD Health)
Source: WebMD Health - December 13, 2017 Category: Consumer Health News Source Type: news

Another Legacy of Terror Attacks: Migraines
Source: HealthDay Related MedlinePlus Pages: Disaster Preparation and Recovery, Headache, Migraine (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - December 13, 2017 Category: Consumer Health News Source Type: news

Witnessing Terror Event Can Lead to Daily Migraines (CME/CE)
(MedPage Today) -- Study done in young survivors of 2011 mass shooting in Norway (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - December 13, 2017 Category: Psychiatry Source Type: news

Springfield Smoked Fish Recalls Smoked Salmon Because Of Possible Health Risk
Springfield Smoked Fish of Springfield, Ma.is recalling its 1lb. packages Prescliced Nova Salmon because they have the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 13, 2017 Category: Food Science Source Type: news

Another Legacy of Terror Attacks: Migraines
WEDNESDAY, Dec. 13, 2017 -- Survivors of terror attacks may be at risk of developing frequent migraines or tension-type headaches, a new study suggests. Norwegian researchers examined the aftermath of a 2011 terrorist attack on a summer camp in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 13, 2017 Category: General Medicine Source Type: news

NeuroBreak: Novel Migraine Drug Advances; Nusinersen Ethics; Trauma-Free Spinal Taps?
(MedPage Today) -- News and commentary from the world of neurology and neuroscience (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - December 12, 2017 Category: Psychiatry Source Type: news

Sinus Headache
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - December 12, 2017 Category: General Medicine Source Type: news

Cold and Flu: Prevention, Symptoms and Treatments
In much of the Northern Hemisphere, December through February is prime time for colds, influenza (flu), and other respiratory illnesses. Don’t let a cold or the flu ruin your holidays! Learn how to protect yourself and your family with these tips from the Food & Drug Administration (FDA): Get vaccinated against flu Wash your hands often Limit exposure to infected people Keep stress in check Eat a balanced diet Get enough sleep Exercise Symptoms Most viral respiratory infections, like a cold, come and go within a few days, with no lasting effects. But some cause serious health problems. In addition, people who u...
Source: NN/LM Middle Atlantic Region Blog - December 11, 2017 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Consumer Health Health Professionals K-12 Public Health Source Type: news

FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults
Galcanezumab is the first of three investigational, non-opioid treatments in Lilly's pain portfolio INDIANAPOLIS, Dec. 11, 2017 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug A... Biopharmaceuticals, FDA Eli Lilly, Galcanezumab, migraine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2017 Category: Pharmaceuticals Source Type: news

FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults
INDIANAPOLIS, Dec. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) to review galcanezumab for the prevention of migraine... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 11, 2017 Category: Drugs & Pharmacology Source Type: news

How Does Pediatric Sj ö gren Syndrome Present?
Discussion Sjögren Syndrome (SS) is named for Swedish ophthalmologist Henrik Sjögren who published a case series in 1933 describing patients with dry eyes and arthritis. SS is a “chronic autoimmune inflammatory exocrinopathy” that is characterized by lymphocytic infiltration of the lacrimal and salivary glands and has various degrees of systematic involvement. Keratoconjunctivitis sicca and xerostomia are the main clinical symptoms. Sicca is a Latin word meaning dry. Dryness of the eyes and mouth without evidence of autoimmune disease is called Sicca syndrome or Sicca complex. SS can be primary or se...
Source: PediatricEducation.org - December 11, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Dec 8 Cardiology News Dec 8 Cardiology News
Mobile ECGs, PFO closure for migraine, AF care, lytic and mechanical removal of VTE and the PSCK9 inhibitor evolocumab are discussed in this week's podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Medical News Today: What is an intractable migraine?
Learn all about status migrainosus, a migraine that lasts for longer than 3 days, also known as intractable migraine. We look at symptoms and treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 8, 2017 Category: Consumer Health News Tags: Headache / Migraine Source Type: news

A scoping review of pain in children following traumatic brain injury: is there more than headache? - Kwan V, Vo M, Noel M, Yeates KO.
AIM: Headache is a common source of pain in children following traumatic brain injury (TBI); however, relatively little is known about non-headache pain in this pediatric population. The present review seeks to map the extant literature to determine the pr... (Source: SafetyLit)
Source: SafetyLit - December 8, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Atraumatic Lumbar Puncture Needles Show Major Benefit in Meta-Analysis
Atraumatic needles more than halve the incidence of headache after lumbar puncture, compared with standard needles, a Lancet meta-analysis finds. Conventional needles have their... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 8, 2017 Category: Primary Care Source Type: news

Mixed migraine results for PFO closure study
Percutaneous closure of patent foramen ovale did not significantly lessen the frequency of migraines in patients with episodic migraines, according to a study published yesterday in the Journal of the American College of Cardiology.  Although the Premium trial missed its primary endpoint, the study met the secondary endpoint of reducing migraine days after PFO closure. A sub-group analysis also found that patients with frequent aura experienced a significant reduction in migraine attacks with PFO closure. One of the trial’s investigators told Medscape that there is validity to right-to-left shunt closu...
Source: Mass Device - December 7, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Neurological Wall Street Beat stjudemedical Source Type: news

PFO Closure for Migraine: Debates Continue as PREMIUM Published PFO Closure for Migraine: Debates Continue as PREMIUM Published
Patient subgroups may benefit, suggest some findings from the sham-controlled trial, at least the third major study of the controversial procedure. Further studies are warranted, says an observer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Sore throat? THIS cheap spray could relieve flu symptoms and pain in SECONDS
SORE throat remedies become increasingly popular during the winter months, as people try to fight symptoms of flu, along with signs of a fever, headache, and a runny nose. (Source: Daily Express - Health)
Source: Daily Express - Health - December 6, 2017 Category: Consumer Health News Source Type: news

The role of negative affect on headache-related disability following traumatic physical injury - Pacella ML, Hruska B, George RL, Delahanty DL.
OBJECTIVE: Acute postinjury negative affect (NA) may contribute to headache pain following physical injury. Early psychiatric-headache comorbidity conveys increased vulnerability to chronic headache-related disability and impairment. Yet, it is unknown whe... (Source: SafetyLit)
Source: SafetyLit - December 5, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Medical News Today: What is a vestibular migraine?
We take a look at vestibular migraines, a type of migraine that involves dizziness and vertigo. Learn about the symptoms, causes, and treatment options. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 5, 2017 Category: Consumer Health News Tags: Headache / Migraine Source Type: news

The experts' guide to banishing headaches
An estimated eight million Britons suffer from migraines, and many more experience headaches at some point. Here, experts explain the types of headache and how to treat them. (Source: the Mail online | Health)
Source: the Mail online | Health - December 5, 2017 Category: Consumer Health News Source Type: news

Chronic post-traumatic headache in children and adolescents: systematic review of prevalence and headache features - Shaw L, Morozova M, Abu-Arafeh I.
The aim of this systematic review is to determine the prevalence and clinical features of chronic post-traumatic headache (CPTH) in children and adolescents. Literature search of PubMed, Embase, Cochrane databases and Google Scholar was carried out for all... (Source: SafetyLit)
Source: SafetyLit - December 4, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

New Drugs Could Prevent Migraine Headaches For Some People
(Source: NPR Health and Science)
Source: NPR Health and Science - December 4, 2017 Category: Consumer Health News Authors: Jon Hamilton Source Type: news

Don’t take ibuprofen during pregnancy, especially if you’re having a boy: Research shows it suppresses testosterone and disrupts male development
(Natural News) Pregnant women are responsible for their child’s health from day one of conception until adulthood. Pregnancy may have some painful side effects such as back aches and migraine, but it should not be a reason to self-medicate with painkillers. Researchers from the Institute of Research in Environmental and Occupational Health (Irset, in its... (Source: NaturalNews.com)
Source: NaturalNews.com - December 3, 2017 Category: Consumer Health News Source Type: news

Migraine is 'not just a headache'
Tania suffers from extreme migraines that cause vomiting. A new treatment could ease that. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 2, 2017 Category: Consumer Health News Source Type: news

Sensitivity and Specificity as Guides to Clinical Decision Making
From headache to helping hand Many of us get headaches and go cross-eyed when we see statistical concepts like sensitivity and specificity in print. Usually, these appear in articles about a diagnostic test's ability to tell you when a condition or disease state is present (i.e., sensitivity) or, conversely, to tell you when that condition or disease state isn't there (i.e., specificity). An initial 12-lead ECG, for example, has a sensitivity of about 68% for diagnosing an acute ST-elevation myocardial infarction (STEMI). That means that a little more than two-thirds of patients who eventually rule-in for MIs are...
Source: JEMS Patient Care - December 1, 2017 Category: Emergency Medicine Authors: Neal Richmond, MD Tags: Patient Care Columns Source Type: news

InFocus: The Miserable, Misunderstood Migraine
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - December 1, 2017 Category: Emergency Medicine Tags: InFocus Source Type: news

CGRP Antagonists the Next Frontier for Migraine Prevention CGRP Antagonists the Next Frontier for Migraine Prevention
Monoclonal antibodies that block the CGRP pathway could be the first mechanism-specific preventive treatments for migraine.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

New drugs could cut frequency of migraines, studies suggest
New, long-acting drugs may hold hope for millions of people who often suffer migraines. Studies of two of these medicines, given as shots every month or so, found they cut the frequency of the notoriously painful and disabling headaches. (Source: CBC | Health)
Source: CBC | Health - November 30, 2017 Category: Consumer Health News Tags: News/Health Source Type: news

Medical News Today: Migraine breakthrough: New drug halves attacks
In a phase III clinical trial of people with episodic migraine, a drug called erenumab was found to cut the number of monthly migraine days by over half. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 30, 2017 Category: Consumer Health News Tags: Headache / Migraine Source Type: news

Drug studies offer hope for migraine sufferers
Studies of two long-acting medicines, given as monthly shots, found they cut the frequency of painful and disabling headaches (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 30, 2017 Category: Consumer Health News Source Type: news

Migraine drug could halve the length of attacks, study shows
Researchers say erenumab is ‘incredibly important step forward’ for condition that affects 8.5 million people in UKA new migraine drug that can halve the length of attacks has been hailed as “the start of real change” in how the condition is treated.Erenumab, a laboratory-made antibody that blocks a neural brain pathway called CGRP, is the first drug in 20 years proven to prevent migraine attacks.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 30, 2017 Category: Science Authors: Staff and agencies Tags: Drugs Health Pharmaceuticals industry UK news World news Biology Science Society Business Source Type: news

Migraine MIRACLE jab could HALVE number of debilitating attacks: set for 2018 NHS approval
A SIMPLE jab could end the misery of migraine for millions of sufferers, scientists claimed last night. (Source: Daily Express - Health)
Source: Daily Express - Health - November 30, 2017 Category: Consumer Health News Source Type: news

New Migraine Drugs Show Promise
Title: New Migraine Drugs Show PromiseCategory: Health NewsCreated: 11/29/2017 12:00:00 AMLast Editorial Review: 11/30/2017 12:00:00 AM (Source: MedicineNet Migraine General)
Source: MedicineNet Migraine General - November 30, 2017 Category: Neurology Source Type: news

Migraine therapy that cut attacks hailed as 'huge deal'
Half the people on one study halved the number of migraines they had each month. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 30, 2017 Category: Consumer Health News Source Type: news

Migraine Prevention: Two Calcitonin Gene-Related Peptide Treatments May Help
Two humanized monoclonal antibodies seem effective in preventing migraine, according to two industry-conducted, phase III trials in the New England Journal of Medicine. The... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 30, 2017 Category: Primary Care Source Type: news

Migraine misery OVER? Simple jab could HALF number of debilitating attacks
A SIMPLE jab could end the misery of migraine for millions of sufferers, scientists claimed last night. (Source: Daily Express - Health)
Source: Daily Express - Health - November 30, 2017 Category: Consumer Health News Source Type: news

Big improvements in stroke care
Almost 90% of eligible patients received thrombolysis Related items fromOnMedica Stroke and other vascular disorders Charity calls for major reorganisation of stroke care Combined oral contraception, migraine and stroke Thousands set to benefit from 'game-changer' stroke treatment Heart attack and stroke risk higher with shingles (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 30, 2017 Category: UK Health Source Type: news

Migraine miracle jab 'could be approved by NHS next year'
The monthly injection, called erenumab, prevents nearly half of migraine attacks for people who have few other treatment options, scientists found. (Source: the Mail online | Health)
Source: the Mail online | Health - November 29, 2017 Category: Consumer Health News Source Type: news

New, long-acting drugs cut frequency of migraine headaches
New, long-acting drugs may hold hope for millions of people who often suffer migraines (Source: ABC News: Health)
Source: ABC News: Health - November 29, 2017 Category: Consumer Health News Tags: Health Source Type: news

New Migraine Drugs Show Promise
The drugs were designed specifically to target a pathway believed to be important in these headaches. (Source: WebMD Health)
Source: WebMD Health - November 29, 2017 Category: Consumer Health News Source Type: news

Aimovig ™ (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
Patients With Episodic Migraine Taking Aimovig Reported Significant and Meaningful Benefits Over Six Months, With Reduced Monthly Migraine Days and Acute Medication Use Fifty Percent of Patients Taking Aimovig 140 mg Had Their Migraine Days Cut by at Least Half - Nearly Three-Fold Higher Odds Compared to Placebo Patients Taking Aimovig Reported Reduced Physical Impairment and Improved Ability to Participate in Daily Activities Based on a Novel Patient-Reported Outcomes Tool Ninety Percent of Patients Completed the Six-Month Study; Data Reinforce the Safety and Tolerability Profile of Aimovig Consistently Seen in the ...
Source: Amgen News Release - November 29, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New Migraine Drugs Show Promise
Source: HealthDay Related MedlinePlus Pages: Medicines, Migraine (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 29, 2017 Category: Consumer Health News Source Type: news

Electrocore closes $70m Series B
Electrocore said today it closed a $70 million Series B round of financing to support the commercial launch of its gammaCore therapy system into the primary headache market. The round was led by investment group Core Ventures II and joined by Merck’s Global Health Innovation Fund, Knoll Capital Management affiliate Gakasa, American Investment Holdings and the Vinik Family Foundation. Proceeds from the round are slated to be used for the commercial launch, as well as further studies, of its gammaCore device with a focus on the primary headache market. Funds will also support continued clinical and scientific developme...
Source: Mass Device - November 29, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Neuromodulation/Neurostimulation electroCore Source Type: news

New Migraine Drugs, Erenumab and Fremanezumab, Show Promise
WEDNESDAY, Nov. 29, 2017 -- Two new migraine drugs have shown promise in late-stage clinical trials. The drugs were designed specifically to target a pathway believed to be important in these headaches. In stage 3 clinical trials, the drugs were... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 29, 2017 Category: General Medicine Source Type: news

FDA-Approved Cefaly(R) Device to Stop Migraines Now Available
Renowned for helping prevent migraine attacks, a new FDA clearance paves way for more Cefaly devices that can now stop a migraine in progress and prevent a future episode too NEW YORK, Nov. 29, 2017 -- (Healthcare Sales & Marketing Network) -- CEFALY ... Devices, Neurology, FDA, Product Launch CEFALY Technology, Cefaly ACUTE, Cefaly PREVENT, migraine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 29, 2017 Category: Pharmaceuticals Source Type: news